| Similar Articles |
|---|
 |
The Motley Fool
October 26, 2006
Jack Uldrich |
Symyx Homes In on the Right Mix New nanomaterials and customers could catalyze the stock of this high-throughput technology and research software company. Investors, this remains one of the better ways to play this sector.   |
The Motley Fool
February 13, 2006
Stephen D. Simpson |
Symyx's Formula for Success: Wait The sizzle of this chemical research expediter is enticing, but be careful not to get burned -- this stock has been pretty volatile over time. |
The Motley Fool
October 29, 2007
Tom Taulli |
Symyx Still Stymied It has been a gruesome year for shareholders of Symyx Technologies, which develops technologies to manage R&D projects for chemical and life sciences companies. So far this year, the stock price has lost about half its value. |
Bio-IT World
August 2005
Johan Bostrom |
Agilent Acquisitions Bolster Portfolio of Products A string of acquisitions is helping Agilent Technologies establish itself as a major player in informatics for analytical laboratories, and its expanding product portfolio has made it a serious player in laboratory analysis automation and software integration. |
Information Today
August 20, 2007
Robert E. Buntrock |
Elsevier to Sell MDL to Symyx Technologies Elsevier buys Beilstein. Elsevier integrates Beilstein into MDL DiscoveryGate. Elsevier sells MDL to Symyx, which had previously purchased IntelliChem and Synthematix. Elsevier keeps Beilstein. These are interesting times in the cheminformatics business. |
Fast Company
March 15, 2007
Tinker Ready |
Not Invented Here The next blockbuster drug could come from anywhere. It's up to Merck's scouts to find it. |
The Motley Fool
December 21, 2006
Brian Lawler |
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. |
